nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—PTGS2—urinary bladder cancer	0.318	1	CbGaD
Mefenamic acid—AKR1C3—Doxorubicin—urinary bladder cancer	0.186	0.473	CbGbCtD
Mefenamic acid—PTGS2—Cisplatin—urinary bladder cancer	0.045	0.114	CbGbCtD
Mefenamic acid—PTGS2—Etoposide—urinary bladder cancer	0.0442	0.112	CbGbCtD
Mefenamic acid—PTGS1—Etoposide—urinary bladder cancer	0.0373	0.095	CbGbCtD
Mefenamic acid—CYP2C8—Fluorouracil—urinary bladder cancer	0.0258	0.0657	CbGbCtD
Mefenamic acid—CYP2C8—Etoposide—urinary bladder cancer	0.0215	0.0548	CbGbCtD
Mefenamic acid—CYP2C9—Fluorouracil—urinary bladder cancer	0.018	0.0458	CbGbCtD
Mefenamic acid—CYP2C9—Cisplatin—urinary bladder cancer	0.0153	0.0389	CbGbCtD
Mefenamic acid—AKR1C2—prostate gland—urinary bladder cancer	0.00919	0.225	CbGeAlD
Mefenamic acid—AKR1C3—Podofilox—Etoposide—urinary bladder cancer	0.00337	1	CbGdCrCtD
Mefenamic acid—CYP2C9—urine—urinary bladder cancer	0.0031	0.0759	CbGeAlD
Mefenamic acid—AKR1C2—lymph node—urinary bladder cancer	0.00293	0.072	CbGeAlD
Mefenamic acid—AKR1C3—prostate gland—urinary bladder cancer	0.00287	0.0703	CbGeAlD
Mefenamic acid—AKR1C3—seminal vesicle—urinary bladder cancer	0.00243	0.0595	CbGeAlD
Mefenamic acid—AKR1C3—smooth muscle tissue—urinary bladder cancer	0.00203	0.0498	CbGeAlD
Mefenamic acid—AKR1C3—urethra—urinary bladder cancer	0.00192	0.0471	CbGeAlD
Mefenamic acid—AKR1C3—vagina—urinary bladder cancer	0.00142	0.0347	CbGeAlD
Mefenamic acid—PTGS1—prostate gland—urinary bladder cancer	0.00101	0.0249	CbGeAlD
Mefenamic acid—PTGS2—prostate gland—urinary bladder cancer	0.00097	0.0238	CbGeAlD
Mefenamic acid—AKR1C3—lymph node—urinary bladder cancer	0.000916	0.0225	CbGeAlD
Mefenamic acid—Acetylsalicylic acid—TP53—urinary bladder cancer	0.000908	0.144	CrCbGaD
Mefenamic acid—PTGS1—seminal vesicle—urinary bladder cancer	0.000858	0.021	CbGeAlD
Mefenamic acid—CYP2C8—renal system—urinary bladder cancer	0.000853	0.0209	CbGeAlD
Mefenamic acid—PTGS2—seminal vesicle—urinary bladder cancer	0.00082	0.0201	CbGeAlD
Mefenamic acid—Diclofenac—UGT2B7—urinary bladder cancer	0.000794	0.126	CrCbGaD
Mefenamic acid—Flurbiprofen—UGT2B7—urinary bladder cancer	0.000778	0.123	CrCbGaD
Mefenamic acid—PTGS1—epithelium—urinary bladder cancer	0.000746	0.0183	CbGeAlD
Mefenamic acid—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000718	0.0176	CbGeAlD
Mefenamic acid—PTGS2—epithelium—urinary bladder cancer	0.000713	0.0175	CbGeAlD
Mefenamic acid—PTGS1—renal system—urinary bladder cancer	0.000692	0.017	CbGeAlD
Mefenamic acid—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000687	0.0168	CbGeAlD
Mefenamic acid—CYP2C8—female reproductive system—urinary bladder cancer	0.000683	0.0167	CbGeAlD
Mefenamic acid—PTGS2—renal system—urinary bladder cancer	0.000661	0.0162	CbGeAlD
Mefenamic acid—PTGS2—urethra—urinary bladder cancer	0.000649	0.0159	CbGeAlD
Mefenamic acid—CYP2C8—vagina—urinary bladder cancer	0.000618	0.0151	CbGeAlD
Mefenamic acid—CYP2C9—female reproductive system—urinary bladder cancer	0.000607	0.0149	CbGeAlD
Mefenamic acid—PTGS1—female reproductive system—urinary bladder cancer	0.000554	0.0136	CbGeAlD
Mefenamic acid—PTGS2—female reproductive system—urinary bladder cancer	0.000529	0.013	CbGeAlD
Mefenamic acid—PTGS1—vagina—urinary bladder cancer	0.000501	0.0123	CbGeAlD
Mefenamic acid—PTGS2—vagina—urinary bladder cancer	0.000479	0.0117	CbGeAlD
Mefenamic acid—Floctafenine—PTGS2—urinary bladder cancer	0.000467	0.0739	CrCbGaD
Mefenamic acid—Diclofenac—CXCL8—urinary bladder cancer	0.000449	0.0711	CrCbGaD
Mefenamic acid—Ketoprofen—CXCL8—urinary bladder cancer	0.000397	0.063	CrCbGaD
Mefenamic acid—PTGS1—lymph node—urinary bladder cancer	0.000324	0.00795	CbGeAlD
Mefenamic acid—PTGS2—lymph node—urinary bladder cancer	0.00031	0.00759	CbGeAlD
Mefenamic acid—Tiaprofenic acid—PTGS2—urinary bladder cancer	0.000301	0.0476	CrCbGaD
Mefenamic acid—Lumiracoxib—PTGS2—urinary bladder cancer	0.000301	0.0476	CrCbGaD
Mefenamic acid—Nepafenac—PTGS2—urinary bladder cancer	0.000286	0.0453	CrCbGaD
Mefenamic acid—Niflumic Acid—PTGS2—urinary bladder cancer	0.000268	0.0425	CrCbGaD
Mefenamic acid—Salsalate—PTGS2—urinary bladder cancer	0.000238	0.0377	CrCbGaD
Mefenamic acid—Meclofenamic acid—PTGS2—urinary bladder cancer	0.000234	0.0371	CrCbGaD
Mefenamic acid—Fenoprofen—PTGS2—urinary bladder cancer	0.000196	0.0311	CrCbGaD
Mefenamic acid—Acetylsalicylic acid—PTGS2—urinary bladder cancer	0.000178	0.0281	CrCbGaD
Mefenamic acid—Salicylic acid—PTGS2—urinary bladder cancer	0.000146	0.0232	CrCbGaD
Mefenamic acid—Dysuria—Epirubicin—urinary bladder cancer	0.000144	0.000917	CcSEcCtD
Mefenamic acid—Dizziness—Thiotepa—urinary bladder cancer	0.000144	0.000916	CcSEcCtD
Mefenamic acid—Stomatitis—Methotrexate—urinary bladder cancer	0.000143	0.000911	CcSEcCtD
Mefenamic acid—Urticaria—Fluorouracil—urinary bladder cancer	0.000143	0.00091	CcSEcCtD
Mefenamic acid—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000143	0.000909	CcSEcCtD
Mefenamic acid—Asthma—Doxorubicin—urinary bladder cancer	0.000143	0.000908	CcSEcCtD
Mefenamic acid—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000142	0.000906	CcSEcCtD
Mefenamic acid—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000141	0.000899	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000141	0.000896	CcSEcCtD
Mefenamic acid—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000141	0.000895	CcSEcCtD
Mefenamic acid—Paraesthesia—Etoposide—urinary bladder cancer	0.00014	0.000894	CcSEcCtD
Mefenamic acid—Haematuria—Methotrexate—urinary bladder cancer	0.00014	0.000891	CcSEcCtD
Mefenamic acid—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00014	0.00089	CcSEcCtD
Mefenamic acid—Dyspnoea—Etoposide—urinary bladder cancer	0.000139	0.000887	CcSEcCtD
Mefenamic acid—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000139	0.000885	CcSEcCtD
Mefenamic acid—Somnolence—Etoposide—urinary bladder cancer	0.000139	0.000885	CcSEcCtD
Mefenamic acid—Vomiting—Thiotepa—urinary bladder cancer	0.000138	0.000881	CcSEcCtD
Mefenamic acid—Pneumonia—Epirubicin—urinary bladder cancer	0.000138	0.00088	CcSEcCtD
Mefenamic acid—Drowsiness—Epirubicin—urinary bladder cancer	0.000137	0.000875	CcSEcCtD
Mefenamic acid—Rash—Thiotepa—urinary bladder cancer	0.000137	0.000874	CcSEcCtD
Mefenamic acid—Dermatitis—Thiotepa—urinary bladder cancer	0.000137	0.000873	CcSEcCtD
Mefenamic acid—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000137	0.000872	CcSEcCtD
Mefenamic acid—Headache—Thiotepa—urinary bladder cancer	0.000136	0.000868	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000136	0.000867	CcSEcCtD
Mefenamic acid—Decreased appetite—Etoposide—urinary bladder cancer	0.000136	0.000865	CcSEcCtD
Mefenamic acid—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000135	0.000862	CcSEcCtD
Mefenamic acid—Renal failure—Epirubicin—urinary bladder cancer	0.000135	0.00086	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000135	0.000859	CcSEcCtD
Mefenamic acid—Body temperature increased—Cisplatin—urinary bladder cancer	0.000135	0.000859	CcSEcCtD
Mefenamic acid—Stomatitis—Epirubicin—urinary bladder cancer	0.000134	0.000853	CcSEcCtD
Mefenamic acid—Jaundice—Epirubicin—urinary bladder cancer	0.000134	0.000853	CcSEcCtD
Mefenamic acid—Constipation—Etoposide—urinary bladder cancer	0.000134	0.000851	CcSEcCtD
Mefenamic acid—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000134	0.00085	CcSEcCtD
Mefenamic acid—Dysuria—Doxorubicin—urinary bladder cancer	0.000133	0.000849	CcSEcCtD
Mefenamic acid—Haemoglobin—Methotrexate—urinary bladder cancer	0.000132	0.000843	CcSEcCtD
Mefenamic acid—Hepatitis—Methotrexate—urinary bladder cancer	0.000132	0.000839	CcSEcCtD
Mefenamic acid—Haemorrhage—Methotrexate—urinary bladder cancer	0.000132	0.000839	CcSEcCtD
Mefenamic acid—Asthenia—Gemcitabine—urinary bladder cancer	0.000131	0.000836	CcSEcCtD
Mefenamic acid—Haematuria—Epirubicin—urinary bladder cancer	0.000131	0.000834	CcSEcCtD
Mefenamic acid—Diclofenac—PTGS2—urinary bladder cancer	0.000131	0.0207	CrCbGaD
Mefenamic acid—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00013	0.000829	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00013	0.000829	CcSEcCtD
Mefenamic acid—Pruritus—Gemcitabine—urinary bladder cancer	0.00013	0.000825	CcSEcCtD
Mefenamic acid—Nausea—Thiotepa—urinary bladder cancer	0.000129	0.000823	CcSEcCtD
Mefenamic acid—Urethral disorder—Methotrexate—urinary bladder cancer	0.000129	0.000823	CcSEcCtD
Mefenamic acid—Feeling abnormal—Etoposide—urinary bladder cancer	0.000129	0.00082	CcSEcCtD
Mefenamic acid—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000129	0.000819	CcSEcCtD
Mefenamic acid—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000128	0.000816	CcSEcCtD
Mefenamic acid—Flurbiprofen—PTGS2—urinary bladder cancer	0.000128	0.0203	CrCbGaD
Mefenamic acid—Pneumonia—Doxorubicin—urinary bladder cancer	0.000128	0.000814	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000128	0.000814	CcSEcCtD
Mefenamic acid—Pruritus—Fluorouracil—urinary bladder cancer	0.000127	0.000811	CcSEcCtD
Mefenamic acid—Drowsiness—Doxorubicin—urinary bladder cancer	0.000127	0.000809	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000126	0.000802	CcSEcCtD
Mefenamic acid—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000125	0.000798	CcSEcCtD
Mefenamic acid—Renal failure—Doxorubicin—urinary bladder cancer	0.000125	0.000796	CcSEcCtD
Mefenamic acid—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000125	0.000793	CcSEcCtD
Mefenamic acid—Urticaria—Etoposide—urinary bladder cancer	0.000124	0.000791	CcSEcCtD
Mefenamic acid—Haemoglobin—Epirubicin—urinary bladder cancer	0.000124	0.000789	CcSEcCtD
Mefenamic acid—Stomatitis—Doxorubicin—urinary bladder cancer	0.000124	0.000789	CcSEcCtD
Mefenamic acid—Jaundice—Doxorubicin—urinary bladder cancer	0.000124	0.000789	CcSEcCtD
Mefenamic acid—Body temperature increased—Etoposide—urinary bladder cancer	0.000124	0.000787	CcSEcCtD
Mefenamic acid—Abdominal pain—Etoposide—urinary bladder cancer	0.000124	0.000787	CcSEcCtD
Mefenamic acid—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000124	0.000787	CcSEcCtD
Mefenamic acid—Haemorrhage—Epirubicin—urinary bladder cancer	0.000123	0.000785	CcSEcCtD
Mefenamic acid—Hepatitis—Epirubicin—urinary bladder cancer	0.000123	0.000785	CcSEcCtD
Mefenamic acid—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000123	0.000784	CcSEcCtD
Mefenamic acid—Tinnitus—Methotrexate—urinary bladder cancer	0.000123	0.000782	CcSEcCtD
Mefenamic acid—Asthenia—Cisplatin—urinary bladder cancer	0.000122	0.000779	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000122	0.000776	CcSEcCtD
Mefenamic acid—Haematuria—Doxorubicin—urinary bladder cancer	0.000121	0.000772	CcSEcCtD
Mefenamic acid—Urethral disorder—Epirubicin—urinary bladder cancer	0.000121	0.00077	CcSEcCtD
Mefenamic acid—Dizziness—Fluorouracil—urinary bladder cancer	0.000119	0.000758	CcSEcCtD
Mefenamic acid—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000119	0.000755	CcSEcCtD
Mefenamic acid—Diarrhoea—Cisplatin—urinary bladder cancer	0.000117	0.000743	CcSEcCtD
Mefenamic acid—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000117	0.000743	CcSEcCtD
Mefenamic acid—Alopecia—Methotrexate—urinary bladder cancer	0.000116	0.000742	CcSEcCtD
Mefenamic acid—Vomiting—Gemcitabine—urinary bladder cancer	0.000116	0.000741	CcSEcCtD
Mefenamic acid—Ketoprofen—PTGS2—urinary bladder cancer	0.000116	0.0184	CrCbGaD
Mefenamic acid—Mental disorder—Methotrexate—urinary bladder cancer	0.000115	0.000735	CcSEcCtD
Mefenamic acid—Rash—Gemcitabine—urinary bladder cancer	0.000115	0.000735	CcSEcCtD
Mefenamic acid—Dermatitis—Gemcitabine—urinary bladder cancer	0.000115	0.000734	CcSEcCtD
Mefenamic acid—Tinnitus—Epirubicin—urinary bladder cancer	0.000115	0.000732	CcSEcCtD
Mefenamic acid—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000115	0.00073	CcSEcCtD
Mefenamic acid—Headache—Gemcitabine—urinary bladder cancer	0.000115	0.00073	CcSEcCtD
Mefenamic acid—Vomiting—Fluorouracil—urinary bladder cancer	0.000114	0.000729	CcSEcCtD
Mefenamic acid—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000114	0.000727	CcSEcCtD
Mefenamic acid—Hepatitis—Doxorubicin—urinary bladder cancer	0.000114	0.000727	CcSEcCtD
Mefenamic acid—Rash—Fluorouracil—urinary bladder cancer	0.000113	0.000723	CcSEcCtD
Mefenamic acid—Dermatitis—Fluorouracil—urinary bladder cancer	0.000113	0.000722	CcSEcCtD
Mefenamic acid—Headache—Fluorouracil—urinary bladder cancer	0.000113	0.000718	CcSEcCtD
Mefenamic acid—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000113	0.000718	CcSEcCtD
Mefenamic acid—Asthenia—Etoposide—urinary bladder cancer	0.000112	0.000714	CcSEcCtD
Mefenamic acid—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000112	0.000712	CcSEcCtD
Mefenamic acid—Pruritus—Etoposide—urinary bladder cancer	0.000111	0.000704	CcSEcCtD
Mefenamic acid—Arrhythmia—Epirubicin—urinary bladder cancer	0.00011	0.000702	CcSEcCtD
Mefenamic acid—Alopecia—Epirubicin—urinary bladder cancer	0.000109	0.000694	CcSEcCtD
Mefenamic acid—Nausea—Gemcitabine—urinary bladder cancer	0.000109	0.000692	CcSEcCtD
Mefenamic acid—Vomiting—Cisplatin—urinary bladder cancer	0.000108	0.000691	CcSEcCtD
Mefenamic acid—Vision blurred—Methotrexate—urinary bladder cancer	0.000108	0.000688	CcSEcCtD
Mefenamic acid—Mental disorder—Epirubicin—urinary bladder cancer	0.000108	0.000688	CcSEcCtD
Mefenamic acid—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000108	0.000687	CcSEcCtD
Mefenamic acid—Rash—Cisplatin—urinary bladder cancer	0.000108	0.000685	CcSEcCtD
Mefenamic acid—Dermatitis—Cisplatin—urinary bladder cancer	0.000107	0.000684	CcSEcCtD
Mefenamic acid—Diarrhoea—Etoposide—urinary bladder cancer	0.000107	0.000681	CcSEcCtD
Mefenamic acid—Nausea—Fluorouracil—urinary bladder cancer	0.000107	0.000681	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000106	0.000678	CcSEcCtD
Mefenamic acid—Tinnitus—Doxorubicin—urinary bladder cancer	0.000106	0.000677	CcSEcCtD
Mefenamic acid—Anaemia—Methotrexate—urinary bladder cancer	0.000106	0.000675	CcSEcCtD
Mefenamic acid—Flatulence—Epirubicin—urinary bladder cancer	0.000106	0.000674	CcSEcCtD
Mefenamic acid—Tension—Epirubicin—urinary bladder cancer	0.000105	0.000671	CcSEcCtD
Mefenamic acid—Nervousness—Epirubicin—urinary bladder cancer	0.000104	0.000664	CcSEcCtD
Mefenamic acid—Malaise—Methotrexate—urinary bladder cancer	0.000103	0.000659	CcSEcCtD
Mefenamic acid—Dizziness—Etoposide—urinary bladder cancer	0.000103	0.000658	CcSEcCtD
Mefenamic acid—Vertigo—Methotrexate—urinary bladder cancer	0.000103	0.000656	CcSEcCtD
Mefenamic acid—Leukopenia—Methotrexate—urinary bladder cancer	0.000103	0.000654	CcSEcCtD
Mefenamic acid—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000102	0.000649	CcSEcCtD
Mefenamic acid—Nausea—Cisplatin—urinary bladder cancer	0.000101	0.000645	CcSEcCtD
Mefenamic acid—Vision blurred—Epirubicin—urinary bladder cancer	0.000101	0.000644	CcSEcCtD
Mefenamic acid—Alopecia—Doxorubicin—urinary bladder cancer	0.000101	0.000642	CcSEcCtD
Mefenamic acid—Mental disorder—Doxorubicin—urinary bladder cancer	0.0001	0.000637	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Epirubicin—urinary bladder cancer	9.96e-05	0.000634	CcSEcCtD
Mefenamic acid—Convulsion—Methotrexate—urinary bladder cancer	9.94e-05	0.000633	CcSEcCtD
Mefenamic acid—Vomiting—Etoposide—urinary bladder cancer	9.94e-05	0.000633	CcSEcCtD
Mefenamic acid—Anaemia—Epirubicin—urinary bladder cancer	9.92e-05	0.000632	CcSEcCtD
Mefenamic acid—Rash—Etoposide—urinary bladder cancer	9.86e-05	0.000628	CcSEcCtD
Mefenamic acid—Dermatitis—Etoposide—urinary bladder cancer	9.85e-05	0.000627	CcSEcCtD
Mefenamic acid—Headache—Etoposide—urinary bladder cancer	9.79e-05	0.000624	CcSEcCtD
Mefenamic acid—Flatulence—Doxorubicin—urinary bladder cancer	9.79e-05	0.000623	CcSEcCtD
Mefenamic acid—Tension—Doxorubicin—urinary bladder cancer	9.75e-05	0.000621	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	9.7e-05	0.000618	CcSEcCtD
Mefenamic acid—Malaise—Epirubicin—urinary bladder cancer	9.68e-05	0.000616	CcSEcCtD
Mefenamic acid—Discomfort—Methotrexate—urinary bladder cancer	9.65e-05	0.000614	CcSEcCtD
Mefenamic acid—Nervousness—Doxorubicin—urinary bladder cancer	9.65e-05	0.000614	CcSEcCtD
Mefenamic acid—Vertigo—Epirubicin—urinary bladder cancer	9.65e-05	0.000614	CcSEcCtD
Mefenamic acid—Syncope—Epirubicin—urinary bladder cancer	9.63e-05	0.000613	CcSEcCtD
Mefenamic acid—Leukopenia—Epirubicin—urinary bladder cancer	9.61e-05	0.000612	CcSEcCtD
Mefenamic acid—Palpitations—Epirubicin—urinary bladder cancer	9.49e-05	0.000604	CcSEcCtD
Mefenamic acid—Confusional state—Methotrexate—urinary bladder cancer	9.44e-05	0.000601	CcSEcCtD
Mefenamic acid—Loss of consciousness—Epirubicin—urinary bladder cancer	9.44e-05	0.000601	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Methotrexate—urinary bladder cancer	9.36e-05	0.000596	CcSEcCtD
Mefenamic acid—Vision blurred—Doxorubicin—urinary bladder cancer	9.36e-05	0.000596	CcSEcCtD
Mefenamic acid—Convulsion—Epirubicin—urinary bladder cancer	9.3e-05	0.000592	CcSEcCtD
Mefenamic acid—Infection—Methotrexate—urinary bladder cancer	9.3e-05	0.000592	CcSEcCtD
Mefenamic acid—Nausea—Etoposide—urinary bladder cancer	9.29e-05	0.000591	CcSEcCtD
Mefenamic acid—Hypertension—Epirubicin—urinary bladder cancer	9.27e-05	0.00059	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Doxorubicin—urinary bladder cancer	9.22e-05	0.000587	CcSEcCtD
Mefenamic acid—Anaemia—Doxorubicin—urinary bladder cancer	9.18e-05	0.000585	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Methotrexate—urinary bladder cancer	9.17e-05	0.000584	CcSEcCtD
Mefenamic acid—Anxiety—Epirubicin—urinary bladder cancer	9.11e-05	0.00058	CcSEcCtD
Mefenamic acid—Skin disorder—Methotrexate—urinary bladder cancer	9.1e-05	0.000579	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	9.08e-05	0.000578	CcSEcCtD
Mefenamic acid—Discomfort—Epirubicin—urinary bladder cancer	9.03e-05	0.000575	CcSEcCtD
Mefenamic acid—Malaise—Doxorubicin—urinary bladder cancer	8.96e-05	0.00057	CcSEcCtD
Mefenamic acid—Dry mouth—Epirubicin—urinary bladder cancer	8.94e-05	0.000569	CcSEcCtD
Mefenamic acid—Vertigo—Doxorubicin—urinary bladder cancer	8.93e-05	0.000568	CcSEcCtD
Mefenamic acid—Anorexia—Methotrexate—urinary bladder cancer	8.93e-05	0.000568	CcSEcCtD
Mefenamic acid—Syncope—Doxorubicin—urinary bladder cancer	8.91e-05	0.000567	CcSEcCtD
Mefenamic acid—Leukopenia—Doxorubicin—urinary bladder cancer	8.89e-05	0.000566	CcSEcCtD
Mefenamic acid—Confusional state—Epirubicin—urinary bladder cancer	8.84e-05	0.000563	CcSEcCtD
Mefenamic acid—Palpitations—Doxorubicin—urinary bladder cancer	8.78e-05	0.000559	CcSEcCtD
Mefenamic acid—Oedema—Epirubicin—urinary bladder cancer	8.76e-05	0.000558	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Epirubicin—urinary bladder cancer	8.76e-05	0.000558	CcSEcCtD
Mefenamic acid—Hypotension—Methotrexate—urinary bladder cancer	8.75e-05	0.000557	CcSEcCtD
Mefenamic acid—Loss of consciousness—Doxorubicin—urinary bladder cancer	8.73e-05	0.000556	CcSEcCtD
Mefenamic acid—Infection—Epirubicin—urinary bladder cancer	8.71e-05	0.000554	CcSEcCtD
Mefenamic acid—Shock—Epirubicin—urinary bladder cancer	8.62e-05	0.000549	CcSEcCtD
Mefenamic acid—Convulsion—Doxorubicin—urinary bladder cancer	8.61e-05	0.000548	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.58e-05	0.000546	CcSEcCtD
Mefenamic acid—Hypertension—Doxorubicin—urinary bladder cancer	8.58e-05	0.000546	CcSEcCtD
Mefenamic acid—Tachycardia—Epirubicin—urinary bladder cancer	8.55e-05	0.000545	CcSEcCtD
Mefenamic acid—Skin disorder—Epirubicin—urinary bladder cancer	8.51e-05	0.000542	CcSEcCtD
Mefenamic acid—Insomnia—Methotrexate—urinary bladder cancer	8.47e-05	0.000539	CcSEcCtD
Mefenamic acid—Anxiety—Doxorubicin—urinary bladder cancer	8.43e-05	0.000537	CcSEcCtD
Mefenamic acid—Paraesthesia—Methotrexate—urinary bladder cancer	8.41e-05	0.000535	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	8.4e-05	0.000535	CcSEcCtD
Mefenamic acid—Discomfort—Doxorubicin—urinary bladder cancer	8.36e-05	0.000532	CcSEcCtD
Mefenamic acid—Anorexia—Epirubicin—urinary bladder cancer	8.35e-05	0.000532	CcSEcCtD
Mefenamic acid—Dyspnoea—Methotrexate—urinary bladder cancer	8.35e-05	0.000532	CcSEcCtD
Mefenamic acid—Somnolence—Methotrexate—urinary bladder cancer	8.32e-05	0.00053	CcSEcCtD
Mefenamic acid—Dry mouth—Doxorubicin—urinary bladder cancer	8.27e-05	0.000527	CcSEcCtD
Mefenamic acid—Dyspepsia—Methotrexate—urinary bladder cancer	8.24e-05	0.000525	CcSEcCtD
Mefenamic acid—Hypotension—Epirubicin—urinary bladder cancer	8.19e-05	0.000521	CcSEcCtD
Mefenamic acid—Confusional state—Doxorubicin—urinary bladder cancer	8.18e-05	0.000521	CcSEcCtD
Mefenamic acid—Decreased appetite—Methotrexate—urinary bladder cancer	8.14e-05	0.000518	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.11e-05	0.000516	CcSEcCtD
Mefenamic acid—Oedema—Doxorubicin—urinary bladder cancer	8.11e-05	0.000516	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.08e-05	0.000515	CcSEcCtD
Mefenamic acid—Infection—Doxorubicin—urinary bladder cancer	8.06e-05	0.000513	CcSEcCtD
Mefenamic acid—Shock—Doxorubicin—urinary bladder cancer	7.98e-05	0.000508	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.94e-05	0.000505	CcSEcCtD
Mefenamic acid—Insomnia—Epirubicin—urinary bladder cancer	7.93e-05	0.000505	CcSEcCtD
Mefenamic acid—Tachycardia—Doxorubicin—urinary bladder cancer	7.91e-05	0.000504	CcSEcCtD
Mefenamic acid—Skin disorder—Doxorubicin—urinary bladder cancer	7.88e-05	0.000501	CcSEcCtD
Mefenamic acid—Paraesthesia—Epirubicin—urinary bladder cancer	7.87e-05	0.000501	CcSEcCtD
Mefenamic acid—Dyspnoea—Epirubicin—urinary bladder cancer	7.81e-05	0.000497	CcSEcCtD
Mefenamic acid—Somnolence—Epirubicin—urinary bladder cancer	7.79e-05	0.000496	CcSEcCtD
Mefenamic acid—Anorexia—Doxorubicin—urinary bladder cancer	7.73e-05	0.000492	CcSEcCtD
Mefenamic acid—Feeling abnormal—Methotrexate—urinary bladder cancer	7.72e-05	0.000491	CcSEcCtD
Mefenamic acid—Dyspepsia—Epirubicin—urinary bladder cancer	7.71e-05	0.000491	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.66e-05	0.000488	CcSEcCtD
Mefenamic acid—Decreased appetite—Epirubicin—urinary bladder cancer	7.62e-05	0.000485	CcSEcCtD
Mefenamic acid—Hypotension—Doxorubicin—urinary bladder cancer	7.58e-05	0.000482	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.57e-05	0.000482	CcSEcCtD
Mefenamic acid—Constipation—Epirubicin—urinary bladder cancer	7.49e-05	0.000477	CcSEcCtD
Mefenamic acid—Urticaria—Methotrexate—urinary bladder cancer	7.44e-05	0.000474	CcSEcCtD
Mefenamic acid—Abdominal pain—Methotrexate—urinary bladder cancer	7.4e-05	0.000471	CcSEcCtD
Mefenamic acid—Body temperature increased—Methotrexate—urinary bladder cancer	7.4e-05	0.000471	CcSEcCtD
Mefenamic acid—Insomnia—Doxorubicin—urinary bladder cancer	7.33e-05	0.000467	CcSEcCtD
Mefenamic acid—Paraesthesia—Doxorubicin—urinary bladder cancer	7.28e-05	0.000464	CcSEcCtD
Mefenamic acid—Dyspnoea—Doxorubicin—urinary bladder cancer	7.23e-05	0.00046	CcSEcCtD
Mefenamic acid—Feeling abnormal—Epirubicin—urinary bladder cancer	7.22e-05	0.00046	CcSEcCtD
Mefenamic acid—Somnolence—Doxorubicin—urinary bladder cancer	7.21e-05	0.000459	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.17e-05	0.000456	CcSEcCtD
Mefenamic acid—Dyspepsia—Doxorubicin—urinary bladder cancer	7.14e-05	0.000454	CcSEcCtD
Mefenamic acid—Decreased appetite—Doxorubicin—urinary bladder cancer	7.05e-05	0.000449	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7e-05	0.000446	CcSEcCtD
Mefenamic acid—Urticaria—Epirubicin—urinary bladder cancer	6.96e-05	0.000443	CcSEcCtD
Mefenamic acid—Constipation—Doxorubicin—urinary bladder cancer	6.93e-05	0.000441	CcSEcCtD
Mefenamic acid—Abdominal pain—Epirubicin—urinary bladder cancer	6.93e-05	0.000441	CcSEcCtD
Mefenamic acid—Body temperature increased—Epirubicin—urinary bladder cancer	6.93e-05	0.000441	CcSEcCtD
Mefenamic acid—Asthenia—Methotrexate—urinary bladder cancer	6.72e-05	0.000428	CcSEcCtD
Mefenamic acid—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.68e-05	0.000425	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.63e-05	0.000422	CcSEcCtD
Mefenamic acid—Pruritus—Methotrexate—urinary bladder cancer	6.62e-05	0.000422	CcSEcCtD
Mefenamic acid—Urticaria—Doxorubicin—urinary bladder cancer	6.44e-05	0.00041	CcSEcCtD
Mefenamic acid—Abdominal pain—Doxorubicin—urinary bladder cancer	6.41e-05	0.000408	CcSEcCtD
Mefenamic acid—Body temperature increased—Doxorubicin—urinary bladder cancer	6.41e-05	0.000408	CcSEcCtD
Mefenamic acid—Diarrhoea—Methotrexate—urinary bladder cancer	6.41e-05	0.000408	CcSEcCtD
Mefenamic acid—Asthenia—Epirubicin—urinary bladder cancer	6.29e-05	0.0004	CcSEcCtD
Mefenamic acid—Pruritus—Epirubicin—urinary bladder cancer	6.2e-05	0.000395	CcSEcCtD
Mefenamic acid—Dizziness—Methotrexate—urinary bladder cancer	6.19e-05	0.000394	CcSEcCtD
Mefenamic acid—Diarrhoea—Epirubicin—urinary bladder cancer	6e-05	0.000382	CcSEcCtD
Mefenamic acid—Vomiting—Methotrexate—urinary bladder cancer	5.95e-05	0.000379	CcSEcCtD
Mefenamic acid—Rash—Methotrexate—urinary bladder cancer	5.9e-05	0.000376	CcSEcCtD
Mefenamic acid—Dermatitis—Methotrexate—urinary bladder cancer	5.9e-05	0.000376	CcSEcCtD
Mefenamic acid—Headache—Methotrexate—urinary bladder cancer	5.87e-05	0.000373	CcSEcCtD
Mefenamic acid—Asthenia—Doxorubicin—urinary bladder cancer	5.82e-05	0.00037	CcSEcCtD
Mefenamic acid—Dizziness—Epirubicin—urinary bladder cancer	5.79e-05	0.000369	CcSEcCtD
Mefenamic acid—Pruritus—Doxorubicin—urinary bladder cancer	5.74e-05	0.000365	CcSEcCtD
Mefenamic acid—Vomiting—Epirubicin—urinary bladder cancer	5.57e-05	0.000355	CcSEcCtD
Mefenamic acid—Nausea—Methotrexate—urinary bladder cancer	5.56e-05	0.000354	CcSEcCtD
Mefenamic acid—Diarrhoea—Doxorubicin—urinary bladder cancer	5.55e-05	0.000353	CcSEcCtD
Mefenamic acid—Rash—Epirubicin—urinary bladder cancer	5.53e-05	0.000352	CcSEcCtD
Mefenamic acid—Dermatitis—Epirubicin—urinary bladder cancer	5.52e-05	0.000351	CcSEcCtD
Mefenamic acid—Headache—Epirubicin—urinary bladder cancer	5.49e-05	0.00035	CcSEcCtD
Mefenamic acid—Dizziness—Doxorubicin—urinary bladder cancer	5.36e-05	0.000341	CcSEcCtD
Mefenamic acid—Nausea—Epirubicin—urinary bladder cancer	5.21e-05	0.000331	CcSEcCtD
Mefenamic acid—Vomiting—Doxorubicin—urinary bladder cancer	5.16e-05	0.000328	CcSEcCtD
Mefenamic acid—Rash—Doxorubicin—urinary bladder cancer	5.11e-05	0.000325	CcSEcCtD
Mefenamic acid—Dermatitis—Doxorubicin—urinary bladder cancer	5.11e-05	0.000325	CcSEcCtD
Mefenamic acid—Headache—Doxorubicin—urinary bladder cancer	5.08e-05	0.000323	CcSEcCtD
Mefenamic acid—Nausea—Doxorubicin—urinary bladder cancer	4.82e-05	0.000307	CcSEcCtD
Mefenamic acid—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	4.36e-05	0.000537	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—JAG1—urinary bladder cancer	4.35e-05	0.000536	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PTGS2—urinary bladder cancer	4.33e-05	0.000533	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—ERCC2—urinary bladder cancer	4.26e-05	0.000524	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	4.23e-05	0.000521	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—RHOA—urinary bladder cancer	4.19e-05	0.000516	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.18e-05	0.000516	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HDAC4—urinary bladder cancer	4.18e-05	0.000515	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	4.15e-05	0.000512	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TERT—urinary bladder cancer	4.15e-05	0.000512	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	4.14e-05	0.00051	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—GSTP1—urinary bladder cancer	4.13e-05	0.000508	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.06e-05	0.0005	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PPARG—urinary bladder cancer	4.04e-05	0.000498	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MTHFR—urinary bladder cancer	4e-05	0.000493	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.99e-05	0.000492	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—TERT—urinary bladder cancer	3.99e-05	0.000492	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	3.99e-05	0.000491	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	3.94e-05	0.000486	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	3.94e-05	0.000485	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NAT1—urinary bladder cancer	3.94e-05	0.000485	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—CREBBP—urinary bladder cancer	3.88e-05	0.000478	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—ERBB2—urinary bladder cancer	3.88e-05	0.000478	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.87e-05	0.000477	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—TYMS—urinary bladder cancer	3.84e-05	0.000473	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—FGFR3—urinary bladder cancer	3.81e-05	0.000469	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—PTGS2—urinary bladder cancer	3.79e-05	0.000467	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—NCOR1—urinary bladder cancer	3.79e-05	0.000467	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—GSTM1—urinary bladder cancer	3.79e-05	0.000467	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PTEN—urinary bladder cancer	3.77e-05	0.000465	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	3.76e-05	0.000464	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.71e-05	0.000457	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—ESR1—urinary bladder cancer	3.7e-05	0.000456	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—TYMP—urinary bladder cancer	3.69e-05	0.000455	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PRSS3—urinary bladder cancer	3.67e-05	0.000452	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—FGFR3—urinary bladder cancer	3.66e-05	0.000451	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—GPX1—urinary bladder cancer	3.63e-05	0.000447	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	3.6e-05	0.000444	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—EP300—urinary bladder cancer	3.6e-05	0.000443	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.59e-05	0.000442	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—ERCC2—urinary bladder cancer	3.56e-05	0.000439	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.55e-05	0.000437	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—S100B—urinary bladder cancer	3.53e-05	0.000434	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	3.47e-05	0.000428	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.47e-05	0.000428	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.46e-05	0.000427	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	3.38e-05	0.000417	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—MTHFR—urinary bladder cancer	3.35e-05	0.000413	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NAT2—urinary bladder cancer	3.34e-05	0.000412	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—LIG1—urinary bladder cancer	3.32e-05	0.000409	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—CDKN1A—urinary bladder cancer	3.31e-05	0.000408	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—PTEN—urinary bladder cancer	3.31e-05	0.000408	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.3e-05	0.000407	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	3.24e-05	0.0004	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CREBBP—urinary bladder cancer	3.24e-05	0.0004	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.21e-05	0.000396	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	3.21e-05	0.000395	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NAT1—urinary bladder cancer	3.21e-05	0.000395	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IGF1—urinary bladder cancer	3.2e-05	0.000395	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PTGS2—urinary bladder cancer	3.18e-05	0.000391	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—NCOR1—urinary bladder cancer	3.17e-05	0.000391	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—EP300—urinary bladder cancer	3.15e-05	0.000389	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.15e-05	0.000389	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CREBBP—urinary bladder cancer	3.12e-05	0.000384	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—SRC—urinary bladder cancer	3.07e-05	0.000378	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	3.06e-05	0.000377	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	2.98e-05	0.000368	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.94e-05	0.000362	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—RHOA—urinary bladder cancer	2.93e-05	0.000362	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.93e-05	0.000361	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	2.93e-05	0.000361	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—RRM2—urinary bladder cancer	2.88e-05	0.000355	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.88e-05	0.000355	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—RHOA—urinary bladder cancer	2.82e-05	0.000347	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.82e-05	0.000347	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.81e-05	0.000347	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TERT—urinary bladder cancer	2.79e-05	0.000344	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PTEN—urinary bladder cancer	2.77e-05	0.000341	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—MYC—urinary bladder cancer	2.75e-05	0.000339	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PPARG—urinary bladder cancer	2.72e-05	0.000335	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—ERBB2—urinary bladder cancer	2.72e-05	0.000335	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—EGFR—urinary bladder cancer	2.69e-05	0.000331	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.68e-05	0.00033	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—HPGDS—urinary bladder cancer	2.67e-05	0.000329	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—ENO2—urinary bladder cancer	2.67e-05	0.000329	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.66e-05	0.000328	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.66e-05	0.000327	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NAT2—urinary bladder cancer	2.65e-05	0.000327	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—EP300—urinary bladder cancer	2.64e-05	0.000326	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.64e-05	0.000325	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—CREBBP—urinary bladder cancer	2.61e-05	0.000322	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—ERBB2—urinary bladder cancer	2.61e-05	0.000322	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTT1—urinary bladder cancer	2.59e-05	0.000319	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CXCL8—urinary bladder cancer	2.58e-05	0.000317	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—FGFR3—urinary bladder cancer	2.56e-05	0.000316	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PTGS2—urinary bladder cancer	2.55e-05	0.000314	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.55e-05	0.000314	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—KRAS—urinary bladder cancer	2.54e-05	0.000313	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ENO2—urinary bladder cancer	2.53e-05	0.000312	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.49e-05	0.000307	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—ESR1—urinary bladder cancer	2.49e-05	0.000307	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IL2—urinary bladder cancer	2.46e-05	0.000303	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.43e-05	0.000299	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—RBX1—urinary bladder cancer	2.4e-05	0.000296	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CCND1—urinary bladder cancer	2.4e-05	0.000296	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.39e-05	0.000295	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—TYMP—urinary bladder cancer	2.39e-05	0.000294	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.36e-05	0.000291	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MMP9—urinary bladder cancer	2.33e-05	0.000287	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.32e-05	0.000286	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—PTEN—urinary bladder cancer	2.32e-05	0.000285	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.29e-05	0.000282	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.29e-05	0.000282	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—CDKN1A—urinary bladder cancer	2.23e-05	0.000275	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PTEN—urinary bladder cancer	2.23e-05	0.000274	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—EP300—urinary bladder cancer	2.21e-05	0.000272	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CREBBP—urinary bladder cancer	2.18e-05	0.000269	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—HRAS—urinary bladder cancer	2.16e-05	0.000266	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.16e-05	0.000266	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IGF1—urinary bladder cancer	2.16e-05	0.000266	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NQO1—urinary bladder cancer	2.15e-05	0.000265	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—JAG1—urinary bladder cancer	2.15e-05	0.000265	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—SRC—urinary bladder cancer	2.15e-05	0.000265	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PTGS2—urinary bladder cancer	2.14e-05	0.000263	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—EP300—urinary bladder cancer	2.12e-05	0.000262	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.12e-05	0.000261	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.12e-05	0.000261	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.11e-05	0.00026	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.09e-05	0.000257	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—SRC—urinary bladder cancer	2.06e-05	0.000254	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.06e-05	0.000253	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.02e-05	0.00025	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—RHOA—urinary bladder cancer	1.97e-05	0.000243	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.95e-05	0.00024	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.94e-05	0.000239	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MYC—urinary bladder cancer	1.92e-05	0.000237	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—EGFR—urinary bladder cancer	1.88e-05	0.000232	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.87e-05	0.00023	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PTEN—urinary bladder cancer	1.86e-05	0.00023	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.86e-05	0.00023	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MYC—urinary bladder cancer	1.85e-05	0.000228	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—ERBB2—urinary bladder cancer	1.83e-05	0.000225	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.82e-05	0.000224	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—EGFR—urinary bladder cancer	1.81e-05	0.000223	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTP1—urinary bladder cancer	1.8e-05	0.000221	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—KRAS—urinary bladder cancer	1.78e-05	0.000219	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—EP300—urinary bladder cancer	1.78e-05	0.000219	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.76e-05	0.000216	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.74e-05	0.000214	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CXCL8—urinary bladder cancer	1.73e-05	0.000214	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.73e-05	0.000213	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.73e-05	0.000213	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.72e-05	0.000211	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.71e-05	0.000211	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—KRAS—urinary bladder cancer	1.71e-05	0.000211	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.67e-05	0.000206	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.67e-05	0.000206	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL2—urinary bladder cancer	1.66e-05	0.000204	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.65e-05	0.000203	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.65e-05	0.000203	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.65e-05	0.000203	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CCND1—urinary bladder cancer	1.61e-05	0.000199	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TP53—urinary bladder cancer	1.58e-05	0.000195	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.58e-05	0.000195	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MMP9—urinary bladder cancer	1.57e-05	0.000193	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—NCOR1—urinary bladder cancer	1.56e-05	0.000193	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—CDKN1A—urinary bladder cancer	1.56e-05	0.000192	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—PTEN—urinary bladder cancer	1.56e-05	0.000192	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.55e-05	0.000191	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.52e-05	0.000187	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—HRAS—urinary bladder cancer	1.51e-05	0.000186	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—EP300—urinary bladder cancer	1.49e-05	0.000183	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ERCC2—urinary bladder cancer	1.47e-05	0.000181	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.46e-05	0.00018	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—HRAS—urinary bladder cancer	1.45e-05	0.000179	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.45e-05	0.000178	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SRC—urinary bladder cancer	1.45e-05	0.000178	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.43e-05	0.000176	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.4e-05	0.000173	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.4e-05	0.000173	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.4e-05	0.000172	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.39e-05	0.000171	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MTHFR—urinary bladder cancer	1.38e-05	0.00017	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.38e-05	0.00017	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TERT—urinary bladder cancer	1.38e-05	0.00017	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.36e-05	0.000168	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.35e-05	0.000166	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.34e-05	0.000165	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.33e-05	0.000163	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.31e-05	0.000161	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.31e-05	0.000161	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MYC—urinary bladder cancer	1.3e-05	0.00016	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—EGFR—urinary bladder cancer	1.27e-05	0.000156	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—FGFR3—urinary bladder cancer	1.26e-05	0.000156	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.25e-05	0.000155	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.23e-05	0.000152	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—KRAS—urinary bladder cancer	1.2e-05	0.000147	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.18e-05	0.000146	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.18e-05	0.000145	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.16e-05	0.000143	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.16e-05	0.000143	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.14e-05	0.00014	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.13e-05	0.000139	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.12e-05	0.000138	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.1e-05	0.000135	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.08e-05	0.000133	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CREBBP—urinary bladder cancer	1.08e-05	0.000133	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.07e-05	0.000131	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.07e-05	0.000131	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TP53—urinary bladder cancer	1.06e-05	0.000131	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.02e-05	0.000126	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—HRAS—urinary bladder cancer	1.02e-05	0.000125	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1e-05	0.000123	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—RHOA—urinary bladder cancer	9.74e-06	0.00012	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.58e-06	0.000118	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	9.44e-06	0.000116	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	9.42e-06	0.000116	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PPARG—urinary bladder cancer	9.39e-06	0.000116	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTGS2—urinary bladder cancer	9.3e-06	0.000115	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.13e-06	0.000113	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CREBBP—urinary bladder cancer	9.02e-06	0.000111	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ERBB2—urinary bladder cancer	9.02e-06	0.000111	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—TYMS—urinary bladder cancer	8.78e-06	0.000108	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	8.67e-06	0.000107	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	8.67e-06	0.000107	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8.31e-06	0.000102	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	8.16e-06	0.000101	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTEN—urinary bladder cancer	8.11e-06	0.0001	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—EP300—urinary bladder cancer	7.74e-06	9.53e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—CDKN1A—urinary bladder cancer	7.71e-06	9.5e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—PTEN—urinary bladder cancer	7.69e-06	9.48e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	7.67e-06	9.45e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PPARG—urinary bladder cancer	7.64e-06	9.41e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	7.34e-06	9.04e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—EP300—urinary bladder cancer	7.33e-06	9.04e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—SRC—urinary bladder cancer	7.13e-06	8.79e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—PTEN—urinary bladder cancer	6.44e-06	7.94e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MYC—urinary bladder cancer	6.39e-06	7.88e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—EGFR—urinary bladder cancer	6.25e-06	7.7e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.22e-06	7.66e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—EP300—urinary bladder cancer	6.14e-06	7.57e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	6.01e-06	7.4e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	5.97e-06	7.36e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KRAS—urinary bladder cancer	5.9e-06	7.28e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTEN—urinary bladder cancer	5.24e-06	6.46e-05	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—HRAS—urinary bladder cancer	5.02e-06	6.19e-05	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—EP300—urinary bladder cancer	5e-06	6.16e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	4.89e-06	6.03e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.26e-06	5.26e-05	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.07e-06	5.01e-05	CbGpPWpGaD
